NAM
ALGS icon

NorthCrest Asset Manangement’s Aligos Therapeutics ALGS Stock Holding History

NorthCrest Asset Manangement’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$84.1K – 773
2025
Q4 		$84.1K Hold
10,000
– – ﹤0.01% 806
2025
Q3 		$98.4K Buy
+10,000
New +$91.4K ﹤0.01% 737

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NorthCrest Asset Manangement's ALGS Position: Q1 2026 in Review

NorthCrest Asset Manangement sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 10,000 shares — an estimated $84.1K sold.

NorthCrest Asset Manangement first reported a position in ALGS in Q3 2025 and held it in 2 quarters. The position peaked at $98.4K in Q3 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • NorthCrest Asset Manangement reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NorthCrest Asset Manangement sold 10,000 Aligos Therapeutics shares in Q1 2026, an estimated $84.1K.
  • NorthCrest Asset Manangement first reported a position in Aligos Therapeutics in Q3 2025 and held it in 2 quarters.
  • NorthCrest Asset Manangement's Aligos Therapeutics position peaked at $98.4K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q1 2026, filed 8 Apr 2026.